Risvutatug rezetecan (Ris-Rez) for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Sep 2026: Trial started, NCT07802704
  2. 3 Sep 2026: Trial registered, NCT07802704

The trials

NCT07802704: A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]

State
Under way
Phase
Phase 3
People
684 planned
Started
1 Sep 2026
Primary completion
5 Dec 2029
Arms
Risvutatug rezetecan (Ris-Rez)
Results
None posted
  1. 1 Sep 2026: Trial started
  2. 3 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.